Movement Alert｜Kymera Therapeutics Falls 7.48% in Regular Trading, Trading at $107.68

Market Focus

Jun 27

On June 27, Kymera Therapeutics fell 7.48% in regular trading, trading at $107.68/share, with Turnover of $125 million.

Within the Biotechnology sector where Kymera Therapeutics belongs, the overall sector showed mixed performance. Among individual stocks, AbbVie up 1.53%, Vertex Pharmaceuticals up 2.81%, Moderna up 11.45%, Gilead Sciences up 2.38%, Apogee Therapeutics down 0.05%.

Kymera Therapeutics is a clinical-stage biopharmaceutical company focused on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's natural protein degradation system. Its proprietary Pegasus targeted protein degradation platform supports its core pipeline, with lead candidate KT-621 being a first-in-class oral STAT6 degrader currently advancing through Phase 2b clinical trials for atopic dermatitis and asthma.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.gotigerhk.com/news/1108515995"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1108515995\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1108515995?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-06-27 01:58","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1108515995","market":"us","top_or_hot":-1,"title":"Movement Alert｜Kymera Therapeutics Falls 7.48% in Regular Trading, Trading at $107.68","media":"Market Focus","content":"<p><p>On June 27, Kymera Therapeutics fell 7.48% in regular trading, trading at $107.68/share, with Turnover of $125 million.</p><p>Within the Biotechnology sector where Kymera Therapeutics belongs, the overall sector showed mixed performance. Among individual stocks, AbbVie up 1.53%, Vertex Pharmaceuticals up 2.81%, Moderna up 11.45%, Gilead Sciences up 2.38%, Apogee Therapeutics down 0.05%.</p><p>Kymera Therapeutics is a clinical-stage biopharmaceutical company focused on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's natural protein degradation system. Its proprietary Pegasus targeted protein degradation platform supports its core pipeline, with lead candidate KT-621 being a first-in-class oral STAT6 degrader currently advancing through Phase 2b clinical trials for atopic dermatitis and asthma.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜Kymera Therapeutics Falls 7.48% in Regular Trading, Trading at $107.68</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜Kymera Therapeutics Falls 7.48% in Regular Trading, Trading at $107.68\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-06-27 01:58</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On June 27, Kymera Therapeutics fell 7.48% in regular trading, trading at $107.68/share, with Turnover of $125 million.</p><p>Within the Biotechnology sector where Kymera Therapeutics belongs, the overall sector showed mixed performance. Among individual stocks, AbbVie up 1.53%, Vertex Pharmaceuticals up 2.81%, Moderna up 11.45%, Gilead Sciences up 2.38%, Apogee Therapeutics down 0.05%.</p><p>Kymera Therapeutics is a clinical-stage biopharmaceutical company focused on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's natural protein degradation system. Its proprietary Pegasus targeted protein degradation platform supports its core pipeline, with lead candidate KT-621 being a first-in-class oral STAT6 degrader currently advancing through Phase 2b clinical trials for atopic dermatitis and asthma.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"KYMR","symbol_name":"Kymera Therapeutics, Inc.","start_time":0,"source_url":"","article_id":"1108515995","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1108515995","pubTimestamp":1782496728,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On June 27, Kymera Therapeutics fell 7.48% in regular trading, trading at $107.68/share, with Turnover of $125 million.Within the Biotechnology sector where Kymera Therapeutics belongs, the overall...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"KYMR":"Kymera Therapeutics, Inc."},"translate_title":"动向提示|Kymera Therapeutics常规交易下跌7.48%，报107.68美元","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"KYMR":1},"content_text":"On June 27, Kymera Therapeutics fell 7.48% in regular trading, trading at $107.68/share, with Turnover of $125 million.Within the Biotechnology sector where Kymera Therapeutics belongs, the overall sector showed mixed performance. Among individual stocks, AbbVie up 1.53%, Vertex Pharmaceuticals up 2.81%, Moderna up 11.45%, Gilead Sciences up 2.38%, Apogee Therapeutics down 0.05%.Kymera Therapeutics is a clinical-stage biopharmaceutical company focused on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's natural protein degradation system. Its proprietary Pegasus targeted protein degradation platform supports its core pipeline, with lead candidate KT-621 being a first-in-class oral STAT6 degrader currently advancing through Phase 2b clinical trials for atopic dermatitis and asthma.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}